ORBICULE
LIVE

Serial Number

79388858

Owner

ARGORNA PHARMACEUTICALS CO., LTD

Attorney

Victoria Friedman

Filing Date

Jul 4, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ORBICULE Trademark

Serial Number: 79388858 • Registration: 7510601

ORBICULE is a trademark filed by ARGORNA PHARMACEUTICALS CO., LTD on July 4, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ARGORNA PHARMACEUTICALS CO., LTD (6 trademarks)

2nd and 4th Floor, Building A, 7 Suida Street,

Entity Type: 99

Trademark Details

Filing Date

July 4, 2023

Registration Date

September 24, 2024

Published for Opposition

July 9, 2024

Goods & Services

Test paper, chemical; chemical preparations in the nature of filtering materials for use in the manufacture of pharmaceuticals; chemical getters; acid proof chemical compositions for use in the manufacture of pharmaceuticals; antioxidants for use in the manufacture of pharmaceuticals; chemical reagents, other than for medical or veterinary purposes; chemical accelerants; chemical preparations for scientific purposes, other than for medical or veterinary use; biochemicals for scientific use; biochemical catalysts

Chemical analysis; scientific laboratory services; chemical research; inspection of drugs for quality control purposes; biomedical research services; development of pharmaceutical preparations and pharmaceuticals; research and development services in the field of chemistry; pharmaceutical research

Pharmaceutical preparations for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical preparations for medical purposes, namely, for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; antimicrobials for dermatologic use; nutritive substances for micro-organisms for medical use; sterilizing preparations; medicinal infusions for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; reagent paper for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical reagents for medical or veterinary purposes

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 26, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 7, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 7, 2025 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 22, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 4, 2025 FICS
FINAL DISPOSITION PROCESSED
Mar 4, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 24, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 24, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 24, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 9, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 19, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 6, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 5, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 24, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 2, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 2, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 18, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 17, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 16, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 9, 2024 REPR